JavaScript is Disabled
Your browser's JavaScript functionality is disabled. It has to be enabled to use this function of ConfTool.
Here you can find information on how to enable JavaScript
If you have any problems, please contact the organizers at parasitologycommunicator@gmail.com.

Conference Agenda

Overview and details of the sessions of this conference. Please select a date or location to show only sessions at that day or location. Please select a single session for detailed view (with abstracts and downloads if available).

Daily Overview

Session

CP13: Ticks, Mites, kissing bugs 10 min talks
Location: Lecture Theatre 3
Session Chair: Katja Fischer, QIMR Berghofer
Session Chair: Xavier Barton, Murdoch University

Presentation 1

IMPACT OF STANDARD SCABICIDE TREATMENT ON SKIN MICROBIAL DYSBIOSIS IN SCABIES

Nuzhat Surve^1,2, Martha Zakrzewski¹, Pallavi Surase², Siddhi Chikhalkar³, Sara Taylor¹, Deepani Fernando¹, Gita Nataraj², Chaya A Kumar², Katja Fischer¹

1: Infection & Inflammation Program, QIMR Berghofer, Brisbane, Australia; 2: Dept. of Microbiology, Seth Gordhandas Sunderdas Medical college and King Edward Memorial Hospital, Mumbai, India; 3: Dept. of Dermatology, Seth Gordhandas Sunderdas Medical college and King Edward Memorial Hospital, Mumbai, India

Background and Aims: Scabies is a neglected tropical skin disease affecting over 400 million people annually, causing a significant public health burden particularly among resource limited regions worldwide. Mite infection alters the skin microbiome and often leads to secondary bacterial skin infections and further serious sequelae. This study investigates whether scabicide therapy fully eliminates pathogens and restores the skin microbiome at the sites of scabies lesion.

Methods: Full-length 16S rRNA sequencing on PacBio platform was performed for 1224 skin scrapings samples collected from scabies lesions and their corresponding uninfected control sites. Participants received a prescribed scabies treatment, i.e. permethrin, ivermectin or a combination of permethrin and ivermectin. Samples were collected at three time points: before treatment, 5–7 days after the initial visit, and 4–6 weeks after the initial visit.

Results: Sequencing identified 114,403 Amplicon sequence variants across 1224 samples and 52 kit controls. Preliminary analysis indicates that the treatments restore bacterial diversity and reduce bacterial pathogen abundance in the healed sites, though the efficiency of pathogen reduction varied between young children and adults.

Conclusions: Early results show the complex interactions between scabies treatment, skin microbiome and host factors such as age with implications for managing secondary infections.